Project Description

Cardio-vascular diseases are one of the biggest threats to public health in Europe. Every year, across the European Union, more than 4 million people lose their lives due to heart failure. Accounting for more than 45% of all deaths, this type of disease is estimated to costs the European economy €210 billion a year. Acute myocardial infarctions, also more commonly known as heart attacks, evolve in about 10% of all cases into a cardiogenic shock (CGS). It is estimated that more than 50’000 people is diagnosed with CGS every year across Europe. Cardiogenic shock is a condition occurring when the degree of heart muscle injury leads to a heart pump failure and the supply of oxygen to vital organs is compromised. Patients with a cardiogenic shock carry a 50% mortality rate for the first 30 days. Comparing this to the only 4% mortality rate for patients suffering a heart attack without a cardiogenic shock shows the severity of the condition. Despite high mortality rates and immense health care expenses, little research has been conducted to improve treatment procedures and current interventions show little impact on the outcomes. EURO SHOCK aims, as the first larger study, to test a novel clinical intervention strategy reducing the high mortality associated with cardiogenic shock and alleviating its burden of chronic heart failure.


To prevent that cardiogenic shock becomes lethal, EURO SHOCK doctors will systematically test the early use of a mechanical support device which oxygenates the blood of the patient. Preliminary scientific studies have shown that the heart – when suffering a heart attack, can benefit from the support of an extracorporeal mechanical oxygenation machine (ECMO). This machine essentially lends the heart the support it needs to recover. EURO SHOCK doctors hope that this new treatment will help increase life chances of patients with cardiogenic shock. The new study aims, not only at improving outcomes for patients suffering from cardiogenic shock, but will also assess the cost effectiveness of this treatment compared to standard treatment. The results of the study will proactively be used to contribute to standards, guidelines and clinical practises for treatment of patient with cardiogenic shock. Thus, EURO SHOCK will ultimately contribute to raising the profile of need for research into cardiogenic shock.

View Project Factsheet

Project Details

accelopment AG, CH
Deutsches Herzzentrum München, DE
University of Glasgow, UK
Katholieke Universiteit Leuven, BE
Ludwig-Maximilians-Universität München, DE
Consorci Institut D’Investicacions Biomediques Augustus Pi i Sunyer, ES
Universitet i Tromsoe, NO
Paula Stradina Liniska Universitates Slimnica AS, LV
Azienda Ospedalierea Papa Giovanni XXIII, IT
University Hospital Antwerpen, BE
University of East Anglia, UK
Universitat Politècnica de Catalunya, ES
Chalice Medical Ltd, UK
01.01-2018 - 31.12.2022
6.5 million euro
Our Services: 
Proposal Writing
Contract Negotiations
Project Management
Project Dissemination
Funding Programme: 
  • H2020-SC1-Health, Demographic Change & Wellbeing
Human Health